Trial Profile
A Phase II Single-Arm Study Evaluating the Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2005
Price :
$35
*
At a glance
- Drugs ABT 510 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Sep 2005 New trial record.